دورية أكاديمية
Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review.
| العنوان: | Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review. |
|---|---|
| المؤلفون: | Pandey, Ambarish, Garg, Sushil, Matulevicius, Susan A, Shah, Amil M, Garg, Jalaj, Drazner, Mark H, Amin, Alpesh, Berry, Jarett D, Marwick, Thomas H, Marso, Steven P, de Lemos, James A, Kumbhani, Dharam J |
| المصدر: | Department of Medicine |
| بيانات النشر: | LVHN Scholarly Works |
| سنة النشر: | 2015 |
| المجموعة: | Lehigh Valley Health Network: LVHN Scholarly Works |
| مصطلحات موضوعية: | Chi-Square Distribution, Diastole, Fibrosis, Heart Failure, Humans, Mineralocorticoid Receptor Antagonists, Randomized Controlled Trials as Topic, Recovery of Function, Stroke Volume, Treatment Outcome, Ventricular Dysfunction, Left, Ventricular Function, Ventricular Remodeling, Department of Medicine, Fellows and Residents, Medicine and Health Sciences |
| الوصف: | BACKGROUND: There has been an increasing interest in use of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure with preserved ejection fraction (HFPEF). However, a comprehensive evaluation of MRA effects on left ventricular (LV) structure and function in these patients is lacking. In this meta-analysis, we evaluated the effects of MRAs on LV structure and function among patients with diastolic dysfunction or HFPEF. METHODS & RESULTS: Randomized, controlled clinical trials evaluating the efficacy of MRAs in patients with diastolic dysfunction or HFPEF were included. The primary outcome was change in E/e', a specific measure of diastolic function. Secondary outcomes included changes in other measures of diastolic function, LV structure, surrogate markers for myocardial fibrosis (carboxy-terminal peptide of procollagen type I [PICP] and amino-terminal peptide of pro-collagen type-II [PIIINP]), blood pressure, and exercise tolerance. In the pooled analysis, MRA use was associated with significant reduction in E/e' (weighted mean difference [WMD] [95% confidence interval {CI}]: -1.68 [-2.03 to -1.33]; P CONCLUSION: MRA therapy in patients with asymptomatic diastolic dysfunction or HFPEF is associated with significant improvement in diastolic function and markers of cardiac fibrosis without a significant change in LV mass or dimensions. |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| العلاقة: | https://scholarlyworks.lvhn.org/medicine/5058Test; https://pubmed.ncbi.nlm.nih.gov/26459931Test/ |
| الإتاحة: | https://scholarlyworks.lvhn.org/medicine/5058Test https://pubmed.ncbi.nlm.nih.gov/26459931Test/ |
| رقم الانضمام: | edsbas.5372F5C2 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |